Venture funding reached a five-year high, but one megadeal drove most of the total while the listing market remained shut.
UK biotech companies raised £2.05 billion in venture capital in the second quarter of 2026, the strongest quarter in five years. The BioIndustry Association reports that £498 million remained after excluding Isomorphic Labs’ record Series B round, which it describes in rounded terms as £1.6 billion.
That underlying total was still close to double the £279 million raised a year earlier, but it was not a broad boom. No UK biotech completed an initial public offering in the first half of 2026. Even so, the UK captured 61% of Europe’s £3.3 billion biotech venture total during the quarter, showing that the funding concentration did not erase its regional lead.
The rebound follows a bruising retreat. Merck & Co. cancelled a £1 billion London research centre, while AstraZeneca paused a £200 million Cambridge expansion. Industry groups counted at least £1.2 billion of investment cancelled or frozen during 2025 and warned that the UK was becoming uninvestable for life sciences. Those projects showed that pricing and access had begun to influence where multinationals put long-term capital.
An ABPI survey found that 79% of responding companies had considered reducing UK operations or investment since January 2024, while 83% said the medicine-pricing rebate directly influenced headcount decisions. Forty-six medicines experienced some negative launch impact, and 29% of respondents expected to reduce full-time employment in 2026. Although industry-supplied, the figures document a retreat beyond two headline projects.
The policy reset
Under the voluntary scheme governing branded-medicine sales to the National Health Service, the headline payment rate on newer medicines had reached 22.9% in 2025. A late-year agreement cut the 2026 headline rate to 14.5% from 1 April and placed a 15% ceiling on it under a UK-US trade framework. The same framework made the UK the only country to secure zero U.S tariffs on pharmaceutical exports, which the government values at least £5 billion a year. The deal also commits Britain to spending about 25% more on innovative medicines.
Other indicators improved alongside the pricing reset. The average time to set up a commercial clinical trial fell from 169 to 122 days, while regulatory reviews typically finished in under 60 days. AstraZeneca restored its £200 million Cambridge project as part of a £300 million UK programme that also includes Macclesfield. The government also counted more than £3 billion of public and private investment commitments over 12 months, including Moderna’s £1 billion ten-year R&D commitment and UCB’s £500 million research hub. The broader life-sciences sector generates about £147 billion in turnover and employs roughly 360,000 people. A £520 million manufacturing fund has also crowded in more than £700 million of investment and created or safeguarded over 1,300 jobs.
A lopsided rebound
The recovery is reaching some smaller firms. The BIA says twice as many companies raised £10 million to £25 million in the first half of 2026 as in all of 2025. Eight seed rounds averaged £6.4 million, Series A deals totalled £190 million and later rounds £225 million. Public exits remained closed, however. Listed companies raised only £58 million in follow-on financing during the second quarter, no UK biotech IPO broke the drought, and Merck & Co. said its cancelled London plans had not changed.
The test ahead
A frozen listing market changes the financing math for founders and early investors. Without an IPO to supply permanent capital or create an exit, promising companies stay private for longer. Every additional year brings more spending on trials, manufacturing, regulatory work and commercial preparation. Venture investors must either commit again, accept dilution from a lower-priced round or wait for a strategic buyer.
Brexit adds another fixed cost for companies running studies or seeking approvals in both the UK and the EU. Venture capital, partnerships, grants and licensing deals remain the main ways a private biotech finances that burden. Executives and investors who also hold eligible publicly traded securities have a separate route to personal liquidity: financing against those listed holdings. It can free cash for follow-on commitments or other needs without requiring an immediate sale. The distinction matters because shares in a private biotech awaiting an IPO are not the same collateral as an established listed position.
The five-year headline high confirms that investors will still pay for exceptional UK science, while AstraZeneca’s return offers an early sign that the policy reset has improved confidence. Neither development establishes a broad recovery. One transaction supplied most of the quarter’s capital, public exits remain shut and at least one multinational has not returned. Until listings reopen and mid-sized rounds deepen, UK biotech will remain unusually dependent on venture investors, pharmaceutical partnerships and strategic acquisitions to carry companies from promising science to commercial scale.
→ More stories like this await on priceofbusiness.com.
There is no ads to display, Please add some
